Theralink Technologies, a precision oncology company with a novel phosphoprotein-based assay for breast cancer, received College of American Pathologists (CAP) Accreditation for its Reverse Phase Protein Array lab in Golden, CO.
 
The Accreditation was based on results of a recent on-site inspection as part of its Accreditation review system. During the process, which is designed to ensure the highest standard of care for all laboratory patients, inspectors examined the laboratory’s records and the quality control of procedures. The CAP inspector also reviewed laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
 
“This is a major milestone for Theralink, as we now have the only commercial Reverse Phase Protein Array laboratory in the United States with CAP accreditation for our Next Generation Proteomic services,” said Mick Ruxin M.D., CEO of Theralink Technologies. “Theralink is now both CLIA-certified and CAP-accredited, demonstrating that our test results and laboratory processes are meeting and exceeding industry standards for clinical testing. CAP accreditation is the champion of laboratory excellence, and cancer patients will potentially benefit with our accreditation.”
 
The College of America Pathologists is a medical society serving nearly 18,000 physician members and the laboratory community globally. It is the world’s largest association composed exclusively of pathologists and is widely considered the leading standard in laboratory quality assurance.